Compare Novo Nordisk A/S (NVO) vs Public Storage (PSA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Public Storage — how do they compare? Novo Nordisk A/S trades at $38.41 (market cap $165.31B), while Public Storage trades at $285.76 (market cap $53.35B). The key difference: Novo Nordisk A/S is far larger — about 3.1× Public Storage's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Public Storage for 130 Days on average.
| NVO | PSA | |
|---|---|---|
Market Cap | $165.31B | $53.35B |
Volume | 11,432,838 | 1,176,034 |
Sector | Health | Real Estate |
52-Week High | $63.98 | $330.47 |
52-Week Low | $35.29 | $258.44 |
Typical Hold Time | 116 Days | 130 Days |
Enterprise Value | $179.56B | $67.62B |
Dividend Yield | 4.71% | 4.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Public Storage (PSA) trades at $286.07, up 1.45% with recent earnings beats and strong profitability metrics including 41.8% net income margin. Technical indicators show bearish momentum with support at $277, while fundamentals reveal stable revenue growth and a $3.00 dividend. The company recently completed its Public Storage Canada acquisition and issued C$400 million in senior notes.
The stock presents a mixed outlook with analyst consensus target of $328.33 offering 15% upside, though technical weakness and valuation premiums pose risks. Key opportunities include operational momentum and reliable yield, while headwinds include oversupply concerns and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Public Storage
Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.
Read more on PSA →
